Date: 2015-07-21
Type of information: Distribution agreement
Compound: Iluvien®
Company: Alimera Sciences (USA - GA) Knight Therapeutics (Canada)
Therapeutic area: Ophtalmological diseases
Type agreement: distribution
Action mechanism:
- corticosteroid. Iluvien® (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant that releases sub-microgram levels of fluocinolone acetonide for up to 36 months for the treatment of chronic diabetic macular edema . The implant provides a therapeutic effect of up to 36 months by delivering sustained sub-microgram levels of fluocinolone acetonide. Iluvien® is injected in the back of the patient's eye to a position that takes advantage of the eye's natural fluid dynamics. The applicator employs a 25-gauge needle, which allows for a self-sealing wound.
Disease: chronic diabetic macular edema (DME)
Details:
- • On July 21, 2015, Alimera Sciences announced that it has signed an exclusive agreement with Knight Therapeutics, a leading Canadian specialty pharmaceutical company, for the distribution in Canada of Iluvien®, Alimera's sustained release intravitreal implant for the treatment of diabetic macular edema. Under the terms of this agreement, Knight will also handle all regulatory and commercial activities for Iluvien® in Canada . Iluvien® currently is not approved for sale in Canada .
Financial terms:
Latest news:
Is general: Yes
